Latest News
Weekly News Roundup | 16 November 2026
Life science news 16 November 2026: the FDA approved Sunharbo, which it calls the first factor XIa inhibitor for stroke prevention. Sunharbo is approved with antiplatelet therapy after a recent ischaemic stroke. Imfinzi with enfortumab vedotin gained approval in...
Latest News
ZW209 Licensing Deal: What Does Roche Get From Zymeworks?
Under the ZW209 licensing deal with Zymeworks, Roche will receive exclusive global rights to develop and commercialise ZW209. In return, Zymeworks is due $55 million upfront and $40 million when a Phase 1b trial begins. It is also eligible for up to $718 million in...
What FDA’s “Healthy” Rule and Front-of-Pack Labelling Mean for Food Makers
Two changes are reshaping what goes on the front of a US food package. The first, a new definition of the "healthy" nutrient content claim, is already law, with enforcement starting on 25 February 2028 [1]. The second, mandatory front-of-pack labelling in the form of...
Life Science Publishing: Our First Year, and Where You Fit In
Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
Imdelltra Imfinzi Approval: When Could First-Line Use Begin?
Amgen and AstraZeneca presented full DeLLphi-305 results at the ESMO Congress in Madrid. The phase 3 trial added Amgen’s Imdelltra (tarlatamab-dlle) to AstraZeneca’s Imfinzi (durvalumab). It cut the risk of death by 58 per cent in extensive-stage small cell lung...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...
Midlife Metabolic Change: How Behaviour, Nutrition and Stress Shape Health
Midlife marks one of the most significant physiological transitions in the human lifespan. For many individuals, particularly those navigating perimenopause and menopause, metabolic stability becomes harder to maintain, appetite signals shift, energy becomes less...
UK Animal Testing Deadline: What December Actually Requires
The UK animal testing deadline that matters most falls at the end of December. By then, regulatory testing on animals for skin irritation, eye irritation and skin sensitisation is meant to stop. It is the largest of a cluster of targets the Replacing Animals in...
AI in IVF: Ethical and Legal Limits of Algorithmic Decision-Making
AI embryo selection tools can support clinical judgment, but current evidence does not justify treating an algorithmic score as a clinical verdict. A prediction is not a decision Artificial intelligence is entering in vitro fertilisation at one of its most...
Autoimmune CAR-T Safety Under Review as Novartis Halts Eight Trials
Autoimmune CAR-T safety has moved to the centre of the cell therapy agenda. Novartis has halted eight clinical studies of its experimental CD19 CAR-T therapy rapcabtagene autoleucel. The company acted after three fatal cases of a severe inflammatory reaction. Bristol...
What a Hospitalist’s Floor Sees That Health AI Doesn’t
Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...
Screen Failures Are Data Too: What They Reveal About Trial Design
A single screen failure tells us something about a patient. A pattern of screen failures may tell us something about the trial. Clinical research is very good at studying the patients who make it into a trial. We analyze their baseline characteristics, laboratory...
Licensing versus Acquisition: How Pharma Chooses
On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
ADHD Management for the Entire Active Day is Within Reach
When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Weekly News Roundup | 31 August 2026
Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...
Terpenes and Cytokine Modulation: The Evidence Gap in Clinical Aromatherapy
Inflammation is one of the most extensively studied biological processes in modern health science—and one of the most misunderstood concepts in clinical aromatherapy, natural-products and beauty. Inflammation is not inherently harmful. It is a coordinated biological...
Avacopan UK Suspension Follows Retracted Trial Data
The avacopan UK suspension took effect on 1 September 2026. The Medicines and Healthcare products Regulatory Agency stopped supply of the medicine to new patients that day. It also signalled its intention to revoke the UK marketing authorisation on 1 March 2027. The...
Midlife Metabolic Change: How Behaviour, Nutrition and Stress Shape Health
Midlife marks one of the most significant physiological transitions in the human lifespan. For many individuals, particularly those navigating perimenopause and menopause, metabolic stability becomes harder to maintain, appetite signals shift, energy becomes less...
UK Animal Testing Deadline: What December Actually Requires
The UK animal testing deadline that matters most falls at the end of December. By then, regulatory testing on animals for skin irritation, eye irritation and skin sensitisation is meant to stop. It is the largest of a cluster of targets the Replacing Animals in...
AI in IVF: Ethical and Legal Limits of Algorithmic Decision-Making
AI embryo selection tools can support clinical judgment, but current evidence does not justify treating an algorithmic score as a clinical verdict. A prediction is not a decision Artificial intelligence is entering in vitro fertilisation at one of its most...
Autoimmune CAR-T Safety Under Review as Novartis Halts Eight Trials
Autoimmune CAR-T safety has moved to the centre of the cell therapy agenda. Novartis has halted eight clinical studies of its experimental CD19 CAR-T therapy rapcabtagene autoleucel. The company acted after three fatal cases of a severe inflammatory reaction. Bristol...
What a Hospitalist’s Floor Sees That Health AI Doesn’t
Two rooms that rarely talk I spend my working life in two rooms that almost never talk to each other. The first is the hospital floor, where I care for several thousand patients a year as an attending physician. The second is the conference room, where I evaluate...
Screen Failures Are Data Too: What They Reveal About Trial Design
A single screen failure tells us something about a patient. A pattern of screen failures may tell us something about the trial. Clinical research is very good at studying the patients who make it into a trial. We analyze their baseline characteristics, laboratory...
Licensing versus Acquisition: How Pharma Chooses
On 26 August 2026, SK Biopharmaceuticals agreed to license an epilepsy platform from Biohaven. Sixteen days earlier, Jazz Pharmaceuticals agreed to buy an epilepsy biotech outright. Same disease area, same month, two opposite structures. The licensing versus...
Lilly Merida Acquisition Bets $2.875bn on Autoantibody Degraders
Eli Lilly has agreed to buy Merida Biosciences for up to $2.875 billion in cash. The Lilly Merida acquisition was announced on 31 August 2026. It hands Lilly a clinical stage platform built to strip single disease causing antibodies out of circulation. The lead...
ADHD Management for the Entire Active Day is Within Reach
When you’re a child, leaving an amusement park after a wondrous day is hard. Adults know a similar feeling after a vacation or the finale of a favorite television series. Of course, it’s always disappointing when an enjoyable experience runs out. Still, the stakes are...
Weekly News Roundup | 31 August 2026
Life science news 31 August 2026: three US approvals, two UK device safety alerts and two licensing deals. Revolution Medicines won approval for a broad RAS-targeted pancreatic cancer drug. AstraZeneca and Ionis presented the full data behind a closely watched heart...
Terpenes and Cytokine Modulation: The Evidence Gap in Clinical Aromatherapy
Inflammation is one of the most extensively studied biological processes in modern health science—and one of the most misunderstood concepts in clinical aromatherapy, natural-products and beauty. Inflammation is not inherently harmful. It is a coordinated biological...
Featured Articles
Further News
Creative Biolabs’ CRISPR Cell Line Development: Plan the Validation First
CRISPR has expanded the possibilities for creating genetically defined cell models, from loss-of-function knockouts to precise knock-ins and stable Cas9-expressing systems. However, successful CRISPR cell line development depends on more than editing efficiency. The...
Autogene Cevumeran Halt Redraws Cancer Vaccine Trial Design
BioNTech and Genentech have stopped a Phase 2 trial of autogene cevumeran in colorectal cancer. An independent data safety monitoring board recommended the termination. The companies confirmed the decision on 28 August 2026. It arrives nine days after a landmark...
Brepocitinib Dermatomyositis Approval Breaks the Steroid-First Pattern
The brepocitinib dermatomyositis approval landed on 27 August 2026. It is the first shift in a treatment field that has barely moved in decades. The US Food and Drug Administration cleared LISRAYA, an oral dual TYK2 and JAK1 inhibitor, for adults with dermatomyositis....
Why Preventive Foot Care Should Be Central to Diabetes Management
Podiatric input is still mostly reactive, despite the significant advancements in diabetes care in recent decades. All too frequently, patients are referred to podiatry only after infections or ulcers have already occurred. This reactive approach is expensive in terms...
Clinical Trials Roundup | 28 Aug 2026
Revolution Medicines’ Rasonque receives FDA approval as what the FDA calls the first in class targeted therapy for metastatic pancreatic cancer, Priovant’s Lisraya is cleared as the first oral therapy indicated for dermatomyositis in adults, Johnson & Johnson’s...
From EHR Data to Real-World Evidence: Health IT Meets R&D
For most of their existence, electronic health records have been treated as administrative infrastructure, a place to document a visit, justify a claim and satisfy a compliance requirement. That framing no longer reflects their potential. The same records that...
Daraxonrasib FDA Approval Sets a New Bar in Pancreatic Cancer
The daraxonrasib FDA approval, granted on 26 August 2026, gives metastatic pancreatic cancer its first approved targeted therapy. Revolution Medicines will sell the drug as Rasonque. The agency cleared it roughly six and a half months ahead of its goal date. For an...
When Meditation Meets the Page: Can Writing Help Us Understand the Mind?
Meditation may help us observe an experience without immediately reacting to it. Expressive writing may help us give that experience language, structure and meaning. What happens when we stop trying to escape an uncomfortable thought or emotion and instead observe it...
Oral GLP-1 Manufacturing: Can Supply Meet Demand?
Oral GLP-1 manufacturing is now the binding constraint in obesity, not patient acceptance. The question is peptide capacity, tabletting lines and capital committed ahead of demand. Two weight loss tablets have reshaped the obesity market in under a year. Novo...
Zanidatamab Approval Resets First-Line HER2 Gastric Cancer Care
The US Food and Drug Administration cleared two zanidatamab regimens on 25 August 2026. The zanidatamab approval covers first-line treatment of HER2-positive advanced gastro-oesophageal adenocarcinoma. It displaces trastuzumab from a first-line backbone that has...
Leverage Trauma-Informed Care to Enhance Adherence to Safety Interventions
Patient trauma can have a significant impact on the ways in which patients interact with the healthcare environment and with its staff. Many patient behaviors can stem from trauma, including lack of adherence to care plans. In the context of patient safety,...
Robotic Gastrectomy Outperforms Laparoscopic Surgery in Japanese Study
Robotic gastrectomy delivers measurably better perioperative outcomes than conventional laparoscopic surgery for gastric cancer, according to a nationwide analysis of Japanese surgical practice covering more than 22,000 patients. Gastric cancer is the fifth most...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.













